Update on the use of Tirzepatide (Mounjaro)

For managing overweight and obesity

NHS Kent and Medway has issued an update on the implementation of the National Institute for Health and Care Excellence (NICE) technology appraisal - TA 1026: Tirzepatide for managing overweight and obesity.

It clarifies that, currently, there should be no prescribing of Mounjaro (tirzepatide) for managing overweight and obesity (NICE TA 1026) in primary care.

Please note, this does not affect those patients suitable for Mounjaro (tirezepatide) in line with NICE guidance on tirzepatide for treating type 2 diabetes (NICE TA 924).